The mean change in HbA 1c from baseline to week 12 was -0.6 % with sitagliptin and -0.2 with placebo, whereas the mean change from baseline to 54 weeks in patients on sitagliptin was -0.7 %. At week 12, the mean change in FPG from baseline was -1.4 mmol/l with sitagliptin and -0.2 with placebo. In patients on hemodialysis, HbA1c and GA levels decreased with alogliptin administration. As compared with the pretreatment levels, HbA1c and GA at 3 and 18 months, respectively, decreased from 7.1 ± 0.2 to 5.8 ± 1.6 % and from 22.5 ± 0.7 to 19.6 ± 0.6 %, respectively, at 24 months.
GLP-1 receptor agonists
Liraglutide Abbreviations: OD = once daily; HbA 1c = glycated hemoglobin; U = unit; FPG = fasting plasma glucose; GA=glycated albumin; BID = bis in die (twice daily); ESRD = end-stage renal disease
